Tuberculosis into the 2010s: Is the glass half full?

Clinical Infectious Diseases

Volumn 49, Issue 4, 2009, Pages 574-583

  Ralph, Anna P ^a,d,e   Anstey, Nicholas M ^a,b,c   Kelly, Paul M ^a,d  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b CHARLES DARWIN UNIVERSITY   (Australia)

^c ROYAL DARWIN HOSPITAL   (Australia)

^d The Australian National University   (Australia)

^e School of Health Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BCG VACCINE; BENZOTHIAZINE DERIVATIVE; BTZ 043; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; LL 3858; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITROIMIDAZOLE DERIVATIVE; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVATIVE; RIFABUTIN; RIFAMPICIN; SQ 609; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BACTERIAL TRANSMISSION; COMORBIDITY; DIRECTLY OBSERVED THERAPY; FUNDING; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MORTALITY; MULTIDRUG RESISTANCE; POLITICS; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; SUPERINFECTION; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

COMMUNICABLE DISEASE CONTROL; HIV INFECTIONS; HUMANS; TUBERCULOSIS;

EID: 67651089506     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/600889     Document Type: Review

References (113)

1. Flynn JL, Chan J. What's good for the host is good for the bug. Trends Microbiol 2005; 13:98-102.
2. Flynn JL, Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol 2003; 15:450-5.
3. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.411. Geneva: World Health Organization, 2009. Available at: http://www.who.int/tb/publications/ global-report/2009/pdf/full-report.pdf. Accessed January 2009.
4. Cox HS, Sibilia K, Feuerriegel S, et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med 2008; 359:2398-400.
5. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
6. Andrews JR, Gandhi NR, Moodley P, et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis 2008; 198:1582-9.
7. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009; 13:6-16.
8. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO report 2008. WHO/HTM/TB/2008.393 ed .Geneva: World Health Organization, 2008.
9. World Health Organization. An expanded DOTS framework for effective tuberculosis control. WHO/CDS/TB/2002.297. Geneva: World Health Organization, 2002.
10. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367:952-5.
11. Dukes Hamilton C, Sterling TR, Blumberg HM, et al. Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin Infect Dis 2007; 45:338-42.
12. Schwartzman K, Oxalade O, Barr R. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005; 353:1008-20.
13. Corcoran N. Mass media. In: Communicating health: strategies for health promotion. London: Sage Publications, 2007:94.
14. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006;6: 710-25.
15. Pai M, Ramsay A, O'Brien R. Evidence-based tuberculosis diagnosis. PLoS Med 2008; 5:e156.
16. Khan MS, Dar O, Sismanidis C, Shah K, Godfrey-Faussett P. Improvement of tuberculosis case detection and reduction of discrepancies between men and women by simple sputum-submission instructions: a pragmatic randomised controlled trial. Lancet 2007; 369: 1955-60.
17. World Health Organization. New WHO policies. 2007. Available at: http://www.who.int/tb/dots/laboratory/policy/en/index2.html. Accessed March 2009.
18. Ramsay A, Yassin MA, Cambanis A, et al. Front-loaded sputum microscopy services: an opportunity to optimise smear-based case detection of tuberculosis in high-prevalence countries. J Trop Med 2009 [Epub ahead of print].
19. Steingart KR, Ramsay A, Pai M. Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert Rev Anti Infect Ther 2007;5:327-31.
20. Marais BJ, Brittle W, Painczyk K, et al. Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clin Infect Dis 2008; 47:203-7.
21. Lumb R, Ardian M, Waramori G, et al. An alternative method for sputum storage and transport for mycobacterium tuberculosis drug resistance surveys. Int J Tuberc Lung Dis 2006; 10:172-7.
22. Bonilla CA, Crossa A, Jave HO, et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS ONE 2008; 3:e2957.
23. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177:787-92.
24. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Res- pir J 2008; 32:1165-74.
25. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): policy statement. Availalable at: http://www.who.int/tb/featuresarchive/ policystatement.pdf. Geneva: World Health Organization, 2008.
26. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update. WHO/HTM/TB/2008.402. Geneva: World Health Organization, 2008. Available at: http://whqlibdoc.who.int/ publications/2008/9789241547581-eng.pdf. Accessed March 2009.
27. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12:128-38.
28. Salomon JA, Lloyd-Smith JO, Getz WM, et al. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med 2006; 3:e273.
29. Lenaerts AJ, Degroote MA, Orme IM. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol 2008; 16:48-54.
30. Murphy DJ, Brown JR. Novel drug target strategies against Mycobacterium tuberculosis. Curr Opin Microbiol 2008; 11:422-7.
31. Charles PG, Grayson ML. The dearth of new antibiotic development: why we should be worried and what we can do about it. Med J Aust 2004; 181:549-53.
32. Glickman SW, Rasiel EB, Hamilton CD, Kubataev A, Schulman KA. Medicine: a portfolio model of drug development for tuberculosis. Science 2006;311:1246-7.
33. Check E. After decades of drought, new drug possibilities flood TB pipeline. Nat Med 2007; 13:266.
34. Kaiser Family Foundation. Open forum II: key issues in TB drug development -day one: welcome and introduction; the TB drug pipeline-present and future. TB Alliance. London, United Kingdom. 2006. Available at: http://www.kaisernetwork.org/health-cast/uploaded-files/121206-tballiance- welcomeandpipeline.pdf. Accessed March 2009.
35. van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009; 53:849-62.
36. Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005; 49:2294-301.
37. Nuermberger E, Mitchison DA. Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility. Am J Respir Crit Care Med 2009; 179:2-3.
38. Veziris N, Ibrahim M, Lounis N, et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009; 179:75-9.
39. Makarov V, Manina G, Mikusova K, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009; 324:801-4.
40. Connolly L, Edelstein P, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Medicine 2007; 4:e120.
41. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of non- replicating persistence. Infect Immun 1996; 64:2062-9.
42. Voskuil MI, Schnappinger D, Visconti KC, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003; 198:705-13.
43. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373:1183-89.
44. Burman WJ, Goldberg S, Johnson JL, et al., Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174:331-8.
45. Senior K. Moving closer to a new tuberculosis vaccine. Lancet Infect Dis 2009; 9:146.
46. McShane H. Vaccine strategies against tuberculosis. Swiss Med Wkly 2009; 139:156-60.
47. Hoft DF. Tuberculosis vaccine development: goals, immunological design and evaluation. Lancet 2008; 372:164-75.
48. Onyebujoh P, Rodriguez W, Mwaba P. Priorities in tuberculosis research. Lancet 2006; 367:940-2.
49. Roy E, Lowrie DB, Jolles SR. Current strategies in TB immunotherapy. Curr Mol Med 2007; 7:373-86.
50. Reljic R. IFN-gamma therapy of tuberculosis and related infections. J Interferon Cytokine Res 2007; 27:353-64.
51. Rook GA, Lowrie DB, Hernandez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J Infect Dis 2007; 196:191-8.
52. de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev 2003:CD001166.
53. Mwinga A, Nunn A, Ngwira B, et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002; 360:1050-5.
54. Fan MY, Chen XR, Wang Ka, et al. Adjuvant effect of Mycobacterium vaccae on treatment of recurrent treated pulmonary tuberculosis: A meta-analysis. Chinese Journal of Evidence-Based Medicine 2007;7: 449-55.
55. von Reyn C, Arbeit R, Mtei L, et al. The DarDar prime-boost TB vaccine trial in HIV infection: final results. In: Program and abstracts of the 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (Paris). Int J Tuberc Lung Dis 2008; 12:S318.
56. Wise J. Tuberculosis vaccine for HIV-infected patients shows promise. Lancet Infect Dis 2008; 8:745.
57. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering ofavitamin D-mediated human antimicrobial response. Science 2006; 311:1770-3.
58. Ralph AP, Kelly PM, Anstey NM. L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis. Trends Microbiol 2008; 16:336-44.
59. Zea AH, Culotta KS, Ali J, et al. Decreased expression of CD3ζ and nuclear transcription factorκ B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J Infect Dis 2006; 194:1385-93.
60. Abba K, Sudarsanam TD, Grobler L, Volmink J. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev 2008:CD006086.
61. Range N, Andersen AB, Magnussen P, Mugomela A, Friis H. The effect of micronutrient supplementation on treatment outcome in patients with pulmonary tuberculosis: a randomized controlled trial in Mwanza, Tanzania. Trop Med Int Health 2005; 10:826-32.
62. Villamor E, Mugusi F, Urassa W, et al. A trial of the effect of micro- nutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. J Infect Dis 2008; 197:1499-505.
63. Africa's Health in 2010 Project, United States Agency for International Development. Nutrition and tuberculosis: a review of the literature and considerations for TB control programs. 2008. Available at: http://www.aidsportal.org/repos/Nutrition%20and%20TB-Final.pdf. Accessed January 2009.
64. Martins N, Morris P, Kelly P. Nutritional enablers to enhance TB treatment adherence. In: Program and abstracts of the 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (Paris). Int J Tuberc Lung Dis 2008; 12(Suppl 2):S15.
65. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008:CD002244.
66. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351:1741-51.
67. Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005; 41:201-8.
68. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009; 48:1429-32.
69. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55:1176.
70. Dheda K, Shean K, Badri M, et al. Extensively drug-resistant tuberculosis. N Engl J Med 2008; 359:2390-1.
71. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment ofextensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008;372:1403-9.
72. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-74.
73. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009; 7:81-7.
74. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1075-82.
75. Espinal M, Farmer P. The Cambridge Declaration: towards clinical trials for drug-resistant tuberculosis. Int J Tuberc Lung Dis 2009;13: 1-2.
76. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:153-61.
77. Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 2006; 3:e241.
78. Horsburgh CR Jr. Primary transmission of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected persons: what does the future hold in store? J Infect Dis 2008;198:1577-8.
79. Basu S, Andrews JR, Poolman EM, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007; 370:1500-7.
80. Escombe AR, Oeser CC, Gilman RH, et al. Natural ventilation for the prevention of airborne contagion. PLoS Med 2007; 4:e68.
81. Escombe AR, Moore DA, Gilman RH, et al. Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission. PLoS Med 2009; 6:e43.
82. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992; 146:1439-44.
83. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-50.
84. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-21.
85. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-6.
86. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14:1985-91.
87. Golub JE, Saraceni V, Cavalcante SC, et al. The impact ofantiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007;21: 1441-8.
88. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423-30.
89. Scano F, Vitoria M, Burman W, Harries AD, Gilks CF, Havlir D. Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis 2008; 12:1370-5.
90. World Health Organization/Joint United Nations Programme for HIV/AIDS. Strengthening health services to fight HIV/AIDS: guidance on provider-initiated HIV testing and counselling in health facilities. Geneva: World Health Organization, 2007.
91. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization, 2006. Available at: http://www.who.int/hiv/ pub/guidelines/artadultguidelines.pdf. Accessed January 2009.
92. Centers for Diseases Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis [online]. Atlanta: Centers for Disease Control and Prevention, 2007.
93. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiret- roviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007; 13:1001-7.
94. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era ofhighlyactive antiretroviral therapy. AIDS 2002; 16:75-83.
95. Velasco M, Castilla V, Sanz J, et al. Effect ofsimultaneous use ofhighly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:148-52.
96. Baleta A. Trial finds simultaneous HIV/tuberculosis treatment beneficial. Lancet Infect Dis 2008; 8:669.
97. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004: CD000171.
98. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41:681-90.
99. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral effectiveness of concomitant use ofrifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004; 37:1166-9.
100. Thorne C, Newell ML. The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf 2005; 4:323-35.
101. Rossouw T. Quantifying antiretroviral risk in pregnancy. S Afr Med J 2007; 97:1014-6.
102. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001; 28:450-3.
103. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530-9.
104. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8:516-23.
105. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009;48:101-7.
106. Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003; 17:2615-22.
107. Roche PW, Krause V, Konstantinos A, et al. Tuberculosis notifications in Australia, 2006. Commun Dis Intell 2008;32:1-11.
108. Clark M, Riben P. Tuberculosis in First Nations communities. Canadian Ministry of Health. 1999. Available at: http://www.hc-sc.gc.ca/fniah- spma/alt-formats/fmhb-dgspm/pdf/pubs/tuberculos/1999-commun-eng.pdf. Accessed March 2009.
109. Smeja C, Brassard P. Tuberculosis infection in an Aboriginal (First Nations) population of Canada. Int J Tuberc Lung Dis 2000; 4:925-30.
110. Centers for Disease Control and Prevention. Trends in tuberculosis- United States, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:249-53.
111. Centers for Disease Control and Prevention. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009; 58:7-10.
112. Grandjean L, Moore DA. Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug- resistant tuberculosis. Curr Opin Infect Dis 2008; 21:454-61.
113. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Tech- nol Assess 2007; 11:1-196.